Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Prognostic Factors, Outcomes and Clinical Characteristics in Patients with Transformed Follicular Lymphoma (t-FL): Cohort Study of 172 Patients

Preetesh Jain, MBBS,MDDM,PhD, Loretta J. Nastoupil, MD, Rashmi Kanagal-Shamanna, MD, Graciela M. Nogueras González, MPH, Mansoor Noorani, Jorge Enrique Romaguera, Luis Fayad, MD, Felipe Samaniego, MD, Jason R. Westin, MD, L. Jeffrey Medeiros, MD, Sattva Neelapu, Michael Wang, MD, Nathan H. Fowler, MD

Blood (2018) 132 (Supplement 1): 1600.

https://doi.org/10.1182/blood-2018-99-118489

Published: 2018

Journal Articles

Clinical and pathological characteristics of HIV- and HHV-8–negative Castleman disease

Li Yu, Meifeng Tu, Jorge Cortes, Zijun Y. Xu-Monette, Roberto N. Miranda, Jun Zhang, Robert Z. Orlowski, Sattva Neelapu, Prajwal C. Boddu, Mary A. Akosile, Thomas S. Uldrick, Robert Yarchoan, L. Jeffrey Medeiros, Yong Li, David C. Fajgenbaum, Ken H. Young

Blood (2017) 129 (12): 1658–1668.

https://doi.org/10.1182/blood-2016-11-748855

Published: 2017

Journal Articles

The Final Report of a Phase I/II Study of Panobinostat in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients (pts) with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

Bei Hu, MD, Anas Younes, MD, Linda Claret, Lei Feng, MS, Jason R. Westin, MD, Nathan Fowler, MD, Sattva Neelapu, MD, Fredrick B. Hagemeister, MD, Maria Alma Rodriguez, MD, Felipe Samaniego, MD, Luis E. Fayad, MD, Loretta J. Nastoupil, MD, Amanda R Copeland, RN, MSN, CNS, Michelle A Fanale, MD, Yasuhiro Oki, MD

Blood (2016) 128 (22): 1833.

https://doi.org/10.1182/blood.V128.22.1833.1833

Published: 2016

Journal Articles

Human Mesenchymal Stem Cells Promote Resistance to Death Signals By Potentiating FGF Signaling in Mantle Cell Lymphoma

Lalit Sehgal, PhD, Rohit Mathur, PhD, Frank K Braun, PhD, Zuzana Berkova, PhD, Sattva Neelapu, MD, Felipe Samaniego, MD

Blood (2014) 124 (21): 5119.

https://doi.org/10.1182/blood.V124.21.5119.5119

Published: 2014

Journal Articles

A Single Center Phase II Trial Of 90 yttrium-Ibritumomab-Tiuxetan Produces High Response Rates As First-Line Therapy For Early Stage B Cell Indolent Lymphoma, Including Bulky Disease

Felipe Samaniego, M.D., M.P.H, Jorge E Romaguera, MD, Nathan Fowler, MD, Michelle A. Fanale, MD, Jatin J. Shah, M.D., Peter McLaughlin, MD, Barbara Pro, MD, Vijairam Selvaraj, MD, Frank K Braun, PhD, Rohit Mathur, PhD, Lei Feng, M.S., Sattva Neelapu, MD, Larry W. Kwak, MD, PhD

Blood (2013) 122 (21): 3039.

https://doi.org/10.1182/blood.V122.21.3039.3039

Published: 2013

Journal Articles

FAS-AS1 Intronic Lncrna and Ibrutinib Negatively Regulate Soluble Fas Production and Sensitize B-Cell Lymphomas To Fas-Mediated Apoptosis

Lalit Sehgal, Ph.D, Frank K Braun, PhD, Rohit Mathur, PhD, Sattva Neelapu, MD, Larry W. Kwak, MD, PhD, Zuzana Berkova, PhD, Felipe Samaniego, M.D., M.P.H

Blood (2013) 122 (21): 5051.

https://doi.org/10.1182/blood.V122.21.5051.5051

Published: 2013

Journal Articles

Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM)

Paolo Anderlini, MD, Rima M. Saliba, Ph.D., Celina Ledesma, B.S., Christina M Chancoco, Tamera Alexander, P.A., Amin Alousi, MD, Chitra M. Hosing, MD, Issa Khouri, MD, Yago Nieto, M.D., Ph.D., Uday R Popat, MD, Elizabeth J Shpall, MD, Michelle A. Fanale, M.D., Yasuhiro Oki, MD, Jorge E Romaguera, MD, Sattva Neelapu, MD, Anas Younes, M.D., Richard E Champlin, MD

Blood (2013) 122 (21): 410.

https://doi.org/10.1182/blood.V122.21.410.410

Published: 2013

Journal Articles

R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL

Yasuhiro Oki, MD, Jason R. Westin, MD, Nathan Fowler, MD, Sattva Neelapu, MD, F.B. Hagemeister, MD, Peter McLaughlin, MD, Larry W. Kwak, MD, PhD, Jorge Enrique Romaguera, Michelle Fanale, MD, Anas Younes, MD, Maria A. Rodriguez, MD, Robert Z. Orlowski, MD, PhD, Michael Wang, M.D., Souzanne T Ouzounian, Felipe Samaniego, M.D., Luis Fayad, MD

Blood (2012) 120 (21): 3707.

https://doi.org/10.1182/blood.V120.21.3707.3707

Published: 2012

Journal Articles

Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma

Jason R. Westin, MD, Fuliang Chu, PhD, Luis E Fayad, MD, Larry W Kwak, MD, PhD, Nathan H Fowler, MD, Jorge E Romaguera, MD, F.B. Hagemeister, MD, Michelle Fanale, MD, Felipe Samaniego, M.D., Rochelle Allen, RN, Lei Feng, Ph.D, Veerabhadran Baladandayuthapani, PhD, Rinat Rotem-Yehudar, PhD, Sattva Neelapu, MD

Blood (2012) 120 (21): 793.

https://doi.org/10.1182/blood.V120.21.793.793

Published: 2012

Journal Articles

Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma

Jianfei Qian, Yuhuan Zheng, Chengyun Zheng, Lijuan Wang, Hong Qin, Sungyoul Hong, Haiyan Li, Yong Lu, Jin He, Jing Yang, Sattva Neelapu, Larry W. Kwak, Jian Hou, Qing Yi

Blood (2012) 119 (1): 161–169.

https://doi.org/10.1182/blood-2011-07-368472

Published: 2012

Includes: Supplemental data

Journal Articles

Expression of B7-H1 in Mantle Cell Lymphoma Leads to Inhibition of T Cell Response to Tumor Cells

Lijuan Wang, MD, PhD, Jianfei Qian, PhD, Yong Lu, PhD, Haiyan Li, MD, PhD, Sungyoul Hong, PhD, Hanying Bao, MD, PhD, Donghua He, MD, PhD, Zhiqiang Liu, PhD, Yuhuan Zheng, PhD, Jin He, PhD, Yongsheng Lan, PhD, Yi Li, MD, Sattva Neelapu, MD, Jing Yang, PhD, Michael Wang, MD, Cai Zhen, MD, PhD, Qing Yi, MD, PhD

Blood (2011) 118 (21): 2643.

https://doi.org/10.1182/blood.V118.21.2643.2643

Published: 2011

Journal Articles

Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without 90 yttrium Ibritumomab Tiuxetan ( 90 YIT) Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results

Blood (2011) 118 (21): 662.

https://doi.org/10.1182/blood.V118.21.662.662

Published: 2011

Journal Articles

HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma

Richard J. Jones, Veerabhadran Baladandayuthapani, Sattva Neelapu, Luis E. Fayad, Jorge E. Romaguera, Michael Wang, Rakesh Sharma, Dajun Yang, Robert Z. Orlowski

Blood (2011) 118 (15): 4140–4149.

https://doi.org/10.1182/blood-2011-03-340323

Published: 2011

Includes: Supplemental data

Journal Articles

Role of Microenvironment In Mantle Cell Lymphoma: IL-6 as An Important Survival Factor for Tumor Cells

Liang Zhang, MD, PhD, Jing Yang, PhD, Jianfei Qian, PhD, Sattva Neelapu, MD, Larry Kwak, MD, PhD, Michael Wang, MD, Qing Yi, MD, PhD

Blood (2010) 116 (21): 3929.

https://doi.org/10.1182/blood.V116.21.3929.3929

Published: 2010

Journal Articles

Targeting Multiple Myeloma with Human Ig Light Chain Specific Cytotoxic T Lymphocytes

Jinsheng Weng, Soung-Chul Cha, Satoko Matsueda, Sattva Neelapu, MD, Larry W. Kwak, MD, PhD

Blood (2010) 116 (21): 3018.

https://doi.org/10.1182/blood.V116.21.3018.3018

Published: 2010

Journal Articles

A Biologic Combination of Lenalidomide and Rituximab for Front-Line Therapy of Indolent B-Cell Non-Hodgkin's Lymphoma.

Nathan Fowler, M.D., Peter McLaughlin, M.D., Fredrick B. Hagemeister, M.D., Larry Kwak, M.D., Ph.D., Michelle Fanale, M.D., Sattva Neelapu, M.D., Luis Fayad, M.D., Barbara Pro, M.D., Crystal Sergent, RN, MSN, Shana R. S. White, B.S., Felipe Samaniego, M.D.

Blood (2009) 114 (22): 1714.

https://doi.org/10.1182/blood.V114.22.1714.1714

Published: 2009

Journal Articles

Analysis of Antigen-Specific T-Cell Responses and Regulatory T Cells Following Sibling Donor Immunization with Patient-Derived Idiotype Vaccine Prior to Non-Myeloablative Allogeneic Stem Cell Transplantation for Multiple Myeloma.

Myriam Foglietta, MD, Sattva Neelapu, M.D., Daniel H. Fowler, Seth M. Steinberg, Larry W. Kwak, Michael R. Bishop

Blood (2009) 114 (22): 2250.

https://doi.org/10.1182/blood.V114.22.2250.2250

Published: 2009

Journal Articles

Stem Cell Transplantation with 90 yttrium Ibritumomab Tiuxetan( 90 YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies.

Blood (2009) 114 (22): 868.

https://doi.org/10.1182/blood.V114.22.868.868

Published: 2009

Journal Articles

Targeting DKK1 for the Immunotherapy of B-Cell Lymphomas.

Jianfei Qian, PhD, Sungyoul Hong, PhD, Liang Zhang, PhD, Yuhuan Zheng, PhD, Haiyan Li, PhD, Jing Yang, PhD, Sattva Neelapu, MD, Qing Yi, MD, PhD

Blood (2009) 114 (22): 465.

https://doi.org/10.1182/blood.V114.22.465.465

Published: 2009

Journal Articles

In Vitro and In Vivo Effects of CT-011, a Humanized Anti–PD-1 Monoclonal Antibody, in Combination with Rituximab against Human B-Cell Lymphomas.

Fuliang Chu, PhD, Myriam Foglietta, MD, Hong Qin, MD, PhD, Rakesh Sharma, Ph.D., Qing Yi, MD, PhD, Galina Rodionov, Rinat Rotem-Yehudar, PhD, Sattva Neelapu, M.D.

Blood (2009) 114 (22): 724.

https://doi.org/10.1182/blood.V114.22.724.724

Published: 2009

NARROW

Prognostic Factors, Outcomes and Clinical Characteristics in Patients with Transformed Follicular Lymphoma (t-FL): Cohort Study of 172 Patients

Clinical and pathological characteristics of HIV- and HHV-8–negative Castleman disease

The Final Report of a Phase I/II Study of Panobinostat in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients (pts) with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

Human Mesenchymal Stem Cells Promote Resistance to Death Signals By Potentiating FGF Signaling in Mantle Cell Lymphoma

A Single Center Phase II Trial Of 90 yttrium-Ibritumomab-Tiuxetan Produces High Response Rates As First-Line Therapy For Early Stage B Cell Indolent Lymphoma, Including Bulky Disease

FAS-AS1 Intronic Lncrna and Ibrutinib Negatively Regulate Soluble Fas Production and Sensitize B-Cell Lymphomas To Fas-Mediated Apoptosis

Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM)

R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL

Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma

Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma

Expression of B7-H1 in Mantle Cell Lymphoma Leads to Inhibition of T Cell Response to Tumor Cells

Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without 90 yttrium Ibritumomab Tiuxetan ( 90 YIT) Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results

HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma

Role of Microenvironment In Mantle Cell Lymphoma: IL-6 as An Important Survival Factor for Tumor Cells

Targeting Multiple Myeloma with Human Ig Light Chain Specific Cytotoxic T Lymphocytes

A Biologic Combination of Lenalidomide and Rituximab for Front-Line Therapy of Indolent B-Cell Non-Hodgkin's Lymphoma.

Analysis of Antigen-Specific T-Cell Responses and Regulatory T Cells Following Sibling Donor Immunization with Patient-Derived Idiotype Vaccine Prior to Non-Myeloablative Allogeneic Stem Cell Transplantation for Multiple Myeloma.

Stem Cell Transplantation with 90 yttrium Ibritumomab Tiuxetan( 90 YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies.

Targeting DKK1 for the Immunotherapy of B-Cell Lymphomas.

In Vitro and In Vivo Effects of CT-011, a Humanized Anti–PD-1 Monoclonal Antibody, in Combination with Rituximab against Human B-Cell Lymphomas.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only